Laurus Labs, a leading research and development driven pharmaceutical company in India, has received approval from the United States Food and Drug Administration (USFDA).
The approval is for Metformin hydrochloride tablets used for the treatment of diabetes in the strengths of 500 mg, 850 mg and 1,000 mg.
The tablets are generic versions of Bristol-Myers Squibb Companys Glucophage tablets in the same strengths.
The product and active pharmaceutical (API) ingredient will be commercialised from company’s Unit 2 located at Atchutapuram, Visakhapatnam in Andhra Pradesh.
Laurus Labs also manufactures APIs in oncology and other therapeutic areas.
Its strategic investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area.
The company is supplying products to some of the largest generic pharmaceutical companies in the world.